Details for Patent: 11,583,539
✉ Email this page to a colleague
Which drugs does patent 11,583,539 protect, and when does it expire?
Patent 11,583,539 protects BYLVAY and is included in one NDA.
This patent has seven patent family members in seven countries.
Summary for Patent: 11,583,539
| Title: | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
| Abstract: | Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters. |
| Inventor(s): | Per-Göran Gillberg, Jan Mattsson, Pat HORN, Paresh Soni |
| Assignee: | Albireo AB |
| Application Number: | US17/548,090 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 11,583,539
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | 11,583,539 | ⤷ Start Trial | METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Start Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | 11,583,539 | ⤷ Start Trial | METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Start Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | 11,583,539 | ⤷ Start Trial | METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Start Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | RX | Yes | Yes | 11,583,539 | ⤷ Start Trial | METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,583,539
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021379076 | ⤷ Start Trial | |||
| Canada | 3196488 | ⤷ Start Trial | |||
| China | 116710100 | ⤷ Start Trial | |||
| European Patent Office | 4243831 | ⤷ Start Trial | |||
| Japan | 2023549226 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
